Abstract

Mitochondrial iron overload in acquired idiopathic sideroblastic anemia (AISA) may be attributable to mutations of mitochondrial DNA (mtDNA), because these can cause respiratory chain dysfunction, thereby impairing reduction of ferric iron (Fe3+) to ferrous iron (Fe2+). The reduced form of iron is essential to the last step of mitochondrial heme biosynthesis. It is not yet understood to which part of the respiratory chain the reduction of ferric iron is linked. In two patients with AISA we identified point mutations of mtDNA affecting the same transmembrane helix within subunit I of cytochrome c oxidase (COX I; ie, complex IV of the respiratory chain). The mutations were detected by restriction fragment length polymorphism analysis and temperature gradient gel electrophoresis. One of the mutations involves a T → C transition in nucleotide position 6742, causing an amino acid change from methionine to threonine. The other mutation is a T → C transition at nt 6721, changing isoleucine to threonine. Both amino acids are highly conserved in a wide range of species. Both mutations are heteroplasmic, ie, they establish a mixture of normal and mutated mitochondrial genomes, which is typical of disorders of mtDNA. The mutations were present in bone marrow and whole blood samples, in isolated platelets, and in granulocytes, but appeared to be absent from T and B lymphocytes purified by immunomagnetic bead separation. They were not detected in buccal mucosa cells obtained by mouthwashes and in cultured skin fibroblasts examined in one of the patients. In both patients, this pattern of involvement suggests that the mtDNA mutation occurred in a self-renewing bone marrow stem cell with myeloid determination. Identification of two point mutations with very similar location suggests that cytochrome c oxidase plays an important role in the pathogenesis of AISA. COX may be the physiologic site of iron reduction and transport through the inner mitochondrial membrane.

SIDEROBLASTIC ANEMIA is characterized by inadequate formation of heme and excessive accumulation of iron in erythroblast mitochondria. Whereas recent molecular biology approaches identified abnormalities of erythroid δ-aminolevulinic acid synthase in the hereditary, X-linked type of sideroblastic anemia,1-7 the pathogenesis of the most prevalent form of sideroblastic anemia, acquired idiopathic sideroblastic anemia (AISA), has remained an enigma. For many years, investigators tried to clarify the disorder by searching for enzyme defects of heme biosynthesis (Fig 1). A major shortcoming of this approach was its inability to explain why the penultimate product of the heme synthetic pathway, protoporphyrin IX, is elevated rather than decreased in most AISA patients.8 In our opinion, this finding provides a strong argument for a possible defect in the last step of heme synthesis, namely insertion of iron into protoporphyrin IX. This step is catalysed by ferrochelatase. However, this enzyme is unlikely to be responsible, because increased red blood cell (RBC) protoporphyrin concentrations in sideroblastic anemia are not correlated with low ferrochelatase activities.9 With normal ferrochelatase activity, and with plentiful iron and protoporphyrin IX, iron is still not inserted into the heme precursor. The likely explanation is that iron is not in the right chemical form. Iron deposits in sideroblastic mitochondria contain iron in the trivalent ferric (Fe3+) state,10 whereas ferrochelatase can only use ferrous iron (Fe2+) for heme synthesis.11 Because Fe2+ is not stable under aerobic conditions, it is necessary for erythropoietic cells to have an enzyme system that can maintain a supply of Fe2+ as a substrate for ferrochelatase. About 20 years ago, reduction of Fe3+ was shown to be accomplished by the respiratory chain as the source of reducing equivalents.12,13 At complete inhibition of mitochondrial respiration, heme synthesis becomes negligible. However, it is not known to which part of the respiratory chain the reduction of ferric iron is linked.

Fig. 1.

Schematic representation of the heme biosynthetic pathway and its connection with the electron transport chain of the inner mitochondrial membrane. (1) 5-Aminolevulinic acid synthase; (2) 5-aminolevulinic acid dehydratase; (3) porphobilinogen deaminase; (4) uroporphyrinogen III synthase; (5) uroporphyrinogen III decarboxylase; (6) coproporphyrinogen III oxidase; (7) protoporphyrinogen III oxidase. Complex I, NADH dehydrogenase; complex II, succinate dehydrogenase; complex III, b/c1-complex = ubiquinol cytochrome c reductase; complex IV, cytochrome c oxidase; Q, coenzyme Q = ubiquinone; c, cytochrome c. The broken line (grey) represents the outer mitochondrial membrane. In accordance with the point mutations identified in mtDNA-encoded subunit I of cytochrome c oxidase, the reduction of Fe3+ to Fe2+ has been placed into complex IV of the respiratory chain.

Fig. 1.

Schematic representation of the heme biosynthetic pathway and its connection with the electron transport chain of the inner mitochondrial membrane. (1) 5-Aminolevulinic acid synthase; (2) 5-aminolevulinic acid dehydratase; (3) porphobilinogen deaminase; (4) uroporphyrinogen III synthase; (5) uroporphyrinogen III decarboxylase; (6) coproporphyrinogen III oxidase; (7) protoporphyrinogen III oxidase. Complex I, NADH dehydrogenase; complex II, succinate dehydrogenase; complex III, b/c1-complex = ubiquinol cytochrome c reductase; complex IV, cytochrome c oxidase; Q, coenzyme Q = ubiquinone; c, cytochrome c. The broken line (grey) represents the outer mitochondrial membrane. In accordance with the point mutations identified in mtDNA-encoded subunit I of cytochrome c oxidase, the reduction of Fe3+ to Fe2+ has been placed into complex IV of the respiratory chain.

We recently hypothesized that, in sideroblastic anemia, one or several of the enzyme complexes of the respiratory chain are disturbed in such a way that efficient reduction of iron no longer occurs.14 Under these circumstances, the imported iron cannot be used for heme synthesis and will accumulate in the mitochondrial matrix. The proposed malfunction could be due to mutations of nuclear DNA or mitochondrial DNA (mtDNA), because both genomes contribute to the assembly of respiratory chain complexes. Human mtDNA is a 16,569-bp circular molecule that codes for the genes of 13 essential polypeptide subunits of the respiratory chain, together with the 12S and 16S ribosomal RNAs and the 22 mitochondrial transfer RNAs that are required for the intramitochondrial translation of the protein-coding units. In recent years, a variety of disorders with predominantly neurologic symptoms have been linked to mutations in mtDNA.15,16 

Our focus on mtDNA is partly explained by the fact that Pearson's syndrome, a rare congenital disorder, points to a relation between mtDNA mutations and sideroblastic anemia. This condition presents in infancy with a variety of symptoms, including refractory sideroblastic anemia, thrombocytopenia, neutropenia, pancreatic exocrine dysfunction, and lactic acidosis.17 The bone marrow shows dysplastic changes including ring sideroblasts and prominent vacuolization of precursor cells.18,19 The cause of Pearson's syndrome was discovered in 1989, when Rötig et al20 found an mtDNA deletion in a patient with the disorder. Investigation of further patients confirmed that large deletions of mtDNA are a constant feature of this disease.21 However, the relation between mtDNA deletions and sideroblastic anemia was not understood. According to our pathogenetic model,14 deficient iron reduction, attributable to respiratory chain dysfunction, provides the missing link.

Having excluded large deletions of mtDNA as a cause of AISA,22 we started looking for short deletions and point mutations. Recently, we reported a patient who had a heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in his bone marrow cells.23 However, this mutation did not help to localize the crucial site of iron reduction and transport through the mitochondrial inner membrane, because mitochondrial tRNA mutations cause a general impairment of mitochondrial protein synthesis and can thus affect all respiratory chain complexes possessing components encoded by mtDNA. More informative in this respect are the two point mutations presented here.

MATERIALS AND METHODS

Case Reports

Patient no. 1. A 58-year-old woman was first evaluated for moderate macrocytic anemia in 1992. The hemoglobin (Hb) level was 11 g/dL, an RBC count of 2.94 × 106/μL, a hematocrit level of 33%, a mean corpuscular volume (MCV) of 112 fL, a mean corpuscular Hb (MCH) level of 37.8 pg, and a mean corpuscular Hb content (MCHC) of 33.7 g/dL. The leukocyte count was 8.5 × 103/μL, and the white blood cell (WBC) differential was 50% neutrophils, 2% bands, 2% eosinophils, 1% basophils, 5% monocytes, and 40% lymphocytes. The platelet count was 596,000/μL. Bone marrow biopsy showed a hypercellular marrow with dysplastic changes in all three myeloid cell lines. On iron staining, 40% of erythroblasts were ring sideroblasts. There was no excess of myeloblasts. A diagnosis of refractory anemia with ring sideroblasts was made (RARS; according to the French-American-British [FAB] classification). Cytogenetic analysis showed a normal karyotype; in particular, there was no evidence of a 5q− abnormality. The patient had psoriatic arthritis since 1979, but was never treated with methotrexate or cyclophosphamide. On follow-up examinations, bone marrow biopsies showed that ring sideroblasts were greater than 50%; there were no significant changes otherwise. No chromosomal abnormalities were found. Until 1996, the course of the disease was uneventful, with Hb values fluctuating between 8.5 and 10 g/dL. In May 1996, the patient received her first blood transfusion because her Hb level had decreased to 8 g/dL. Meanwhile, transfusion of 2 U of packed RBCs is required every 3 to 4 weeks. In the bone marrow, there has been no evidence of progression toward a more advanced type of myelodysplastic syndrome (MDS).

Patient no. 2. A 68-year-old man presented with exertional dyspnea and fatigue in December 1989. The Hb level was 7.8 g/dL, the MCV was 77.7 fL, the MCH was 32.2 pg, and the serum ferritin level was 664 μg/mL. The leukocyte count was 3.8 × 103 μL, and the WBC differential was 27% neutrophils, 1% bands, 3% eosinophils, 3% monocytes, and 66% lymphocytes. The platelet count was 338,000/μL. Bone marrow biopsy showed hyperplasia and dysplasia of the erythroid series, with megaloblastoid changes and nuclear lobulation and fragmentation. Iron staining showed 70% to 80% ring sideroblasts. Multinucleated megakaryocytes were found. Granulocytopoiesis appeared inconspicuous, and there was no excess of blasts. A diagnosis of RARS was made. In addition, the patient was found to have a multinodular goiter and to be hyperthyroid. He was successfully treated with radioactive iodine. In March 1990, a control bone marrow biopsy showed no significant change, but the patient became transfusion dependent. In September 1991, anemia worsened, bone marrow biopsy showed greater than 90% ring sideroblasts, and cytogenetic examination was abnormal for the first time [in 4 of 20 mitoses, a 5q− abnormality was found, ie, del(5) (q13-14)].

The patient was entered into a pilot study of all-trans retinoic acid24 and responded with an increase in Hb values up to 11.8 g/dL. Ring sideroblasts in the bone marrow decreased to 45% (July 1992). The ferritin level was 385 ng/mL. In January, 1993, anemia worsened again, a bone marrow biopsy showed 70% ring sideroblasts, and karyotype analysis confirmed the 5q− anomaly. The patient received a second trial of ATRA until June 1993. He responded again, became independent of transfusions, and showed an Hb level of 10.2 g/dL. The disease remained stable from 1993 to 1995, when the patient turned up for a follow-up examination: Hb level of 11 g/dL, RBC count of 4.52 × 106 /μL, hematocrit level of 34.6%, reticulocytes level of 13.4%, and MCV of 76.7 fL. The platelet count was 227,000/μL. Bone marrow biopsy showed dysplastic changes in all three cell lines, including some megakaryocytes with nonlobulated nuclei. Ring sideroblasts were 90%. Karyotype analysis showed 5q−. Despite the high proportion of ring sideroblasts, Hb levels have remained stable.

Preparation of Cell Fractions

The patients were part of a series of 20 patients with MDS whose bone marrow samples were subjected to restriction fragment length polymorphism (RFLP) screening for mtDNA mutations. Among those 20 patients, 12 had sideroblastic anemia. Fifty hematologically normal individuals (cardiac surgery patients) were specifically screened for the mutations of cytochrome c oxidase (COX) at nucleotide positions 6721 and 6742 that we identified in AISA patients; bone marrow samples from the controls had been obtained for a previous study on mtDNA deletions.25 In the two patients under discussion, mtDNA was extracted from an unfractionated bone marrow sample and from peripheral blood cells of different lineages. Platelet-rich plasma was obtained from citrated blood samples by centrifugation at 100g for 15 minutes at room temperature. Contaminating blood cells were removed by centrifugation at 200g for 10 minutes. Platelets were pelleted from the supernatant by centrifugation at 1,000g for 10 minutes and resuspended in phosphate-buffered saline. Granulocytes were enriched by depletion of peripheral blood mononuclear cells through density gradient centrifugation with Lymphoprep 1.077 (Nycomed, Oslo, Norway). A 200 μL sample from the granulocyte/erythrocyte pellet was used for DNA extraction. Erythrocytes do not contain mtDNA,26 because mitochondria are eliminated during the reticulocyte stage.27 Therefore, mtDNA isolated from the granulocyte/erythrocyte pellet mainly derives from mature peripheral blood granulocytes, apart from a small contamination by reticulocyte mtDNA. For isolation of B and T lymphocytes from EDTA-anticoagulated blood, immunomagnetic beads (Dynabeads M-450 Pan-B [CD19] and Dynabeads M-450 Pan-T [CD2], respectively) were used according to the recommendations of the manufacturer (Dynal, Oslo, Norway). With antibody-coated beads still bound to the cell surface, lymphocytes were entered into the cell lysis step of the DNA extraction procedure. After cell lysis, beads were removed with a magnet. Buccal mucosa cells were pelleted from a vigorous mouthwash performed with 20 mL normal saline and depleted of contaminating granulocytes by density gradient centrifugation with Nycoprep 1.150 (Nycomed). A skin biopsy (right buttock) was obtained from patient no. 2, and fibroblast cultures were established by outgrowth from this biopsy according to a standard method.28 Cells were grown to confluency in Dulbecco's modified Eagle's Medium (Flow, Meckenheim, Germany) supplemented with sodium ascorbate (50 μg/mL), glutamine (300 μg/mL), penicillin (400 μg/mL), streptomycin (50 μg/mL), and 10% fetal calf serum (FCS) on tissue culture dishes in a humidified atmosphere of 5% CO2 and 95% air at 37°C.

Colony Assay of Hematopoietic Cells

Mononuclear cells were obtained from peripheral blood (PB-MNC) through density gradient centrifugation with Lymphoprep 1.077 (Nycomed), washed three times in RPMI 1640 medium, and plated in tissue culture-grade 35-mm Petri dishes (2 × 105 cells per dish) in a volume of 1 mL MethoCult H4433 (StemCell Technologies, Vancouver, British Columbia, Canada), containing 0.9% methylcellulose, 5% serum (containing phytohemagglutinin-leukocyte conditioned medium [PHA-LCM]), 30% FCS, 10% bovine serum albumin, 13% Iscove's medium, erythropoietin (150 U/mL), 2-mercaptoethanol (0.1 mol/L), and L-glutamine (200 mmol/L). After 14 days of incubation at 37°C and 5% CO2 , colonies and clusters were examined using an inverted microscope. For polymerase chain reaction (PCR) amplification of a particular COX I segment of mtDNA, individual colonies were picked with a micropipette and entered directly into PCR reaction mixtures (before adding specific primers and polymerase).

DNA Isolation

Total DNA was isolated from the various cell samples using the QIAamp Kit (Qiagen, Hilden, Germany), which is based on cell lysis in the presence of guanidine hydrochloride and subsequent binding of DNA to an anion-exchange resin in a spin-column. The procedure ensures extraction of cytoplasmic (eg, mitochondrial) DNA in addition to nuclear DNA.

mtDNA Amplification

mtDNA was amplified in 17 overlapping segments using the PCR. The exact position of segments according to the standard Cambridge sequence29 and the respective primer sequences were as previously reported.23 DNA was amplified using 35 cycles of denaturation (1 minute at 94°C), annealing (30 seconds at 55°C to 71°C, depending on the pair of primers used), and extension (60 seconds at 72°C). The 100 μL PCR reactions contained 10 mmol/L KCl, 20 mmol/L Tris-HCl (pH 8.8), 10 mmol/L (NH4 )2SO4 , 4 mmol/L MgS04 , 400 μmol/L of each dNTP, 50 pmol of each primer, and 1 U of Vent DNA polymerase (New England Biolabs, Dreieich, Germany). Double-stranded PCR products were purified with a commercial DNA purification system (Wizard PCR Preps; Promega, Heidelberg, Germany), separated in 1% agarose gels, and visualized by ethidium bromide staining.

RFLP Analysis

Each amplified mtDNA segment was entered into 20 different restriction enzyme digestions using Alu I, BamHI, Cfo I, Dde I, EcoRI, Hae II, Hae III, HincII, HindIII, HinfI, Hpa I, Msp I, Pvu II, Rsa I, Sac I, Sca I, Stu I, Taq I, Tru9I, and Xba I. Endonucleases were purchased from Boehringer Mannheim (Mannheim, Germany). All restriction enzyme reactions were performed according to manufacturer's recommendations, using approximately 100 to 200 ng of PCR-generated DNA for digestion with 5 U of enzyme. Restriction fragments were separated by electrophoresis in 3.5% Visigel matrix (Stratagene, Heidelberg, Germany) and visualized by ethidium bromide staining and UV illumination.

Heteroduplex Analysis by Temperature Gradient Gel Electrophoresis (TGGE)

Point mutations in double-stranded DNA can be detected by denaturing-gradient gel electrophoresis (DGGE)30 or TGGE,31,32 because mutations alter the denaturation pattern of double-stranded DNA at the site of the mutation and in its neighborhood. The sensitivity of TGGE analysis is greatly enhanced through heteroduplex generation. During a denaturation/renaturation cycle, hybrids are formed between wild-type DNA fragments and homologous fragments carrying the mutation. The mismatch in the double helix at the site of the mutation leads to significant lowering of the midpoint melting temperature of the heteroduplex fragments. When exposed to increasing temperatures during electrophoresis (the TGGE procedure), heteroduplex hybrids show partial denaturation earlier than homoduplexes do. Because early partial denaturation causes early retardation in the gel, heteroduplexes can be resolved from homoduplex molecules by TGGE.

In the two patients reported, intraindividual heteroduplex analysis was performed, ie, TGGE was used to examine whether heteroduplexes formed after PCR amplification of a mtDNA fragment of interest. This only happens when there is coexistence of wild-type and mutated mtDNA in the patient's sample, which is also called heteroplasmy. Among other segments of mtDNA, a 420-bp segment carrying the COX I mutation was amplified by PCR using primers A (nt 6504-6523), 5′-GTCCTAGCTGCTGGCATCAC-3′, and B (nt 6923-6904), 5′-TCAGAGCACTGCAGCAGATC-3′. PCR was followed by quantitative denaturation of the PCR product (heating in 4 mol/L urea at 95°C for 5 minutes) and subsequent renaturation (incubation at 50°C for 20 minutes). Samples were then loaded onto thin polyacrylamide gels (5%) covalently bound to polyethylene gel support films. After electrophoresis, bands of heteroduplex- and homoduplex-DNA were visualized by silver staining. TGGE equipment was purchased from Qiagen.

Sequencing

For sequencing of the region of interest, mtDNA from bone marrow was amplified using a modified primer A (A-EcoRI) and primer B. Primer A-EcoRI (5′-GGCG ↓ AATTC GTCCTAGCTGCTGGCATCAC-3′) was designed to introduce a restriction site for EcoRI. PCR was performed as described above, with an annealing temperature of 59°C and an extension time of 30 seconds, yielding a 429-bp fragment. The PCR product was purified with QIAamp spin columns (Qiagen) and digested with EcoRI and Pst I to yield a shortened fragment 416 bp in length. The digested DNA was extracted with a mixture of phenol and chloroform (70:30), brought to a 0.3 mol/L concentration of sodium acetate, and precipitated with 2.5 vol of ethanol. Using T4 DNA-Ligase, the 416-bp fragment was ligated into the sequencing vector pUC19,33 which had been digested with the same two enzymes (EcoRI and Pst I). After transformation into Escherichia coli strain DHαF′, white colonies were selected on Luria broth (LB) medium containing 150 mg/L ampicillin and X-Gal.34 Plasmid DNA from transformants was prepared using Tip20 columns (Qiagen) and double-stranded DNA was sequenced with the Sequenase kit (US Biochemicals, Cleveland, OH) using 35S-dATP, according to the method of Sanger et al.35 

RESULTS

In two patients with AISA we identified point mutations of mtDNA in the region encoding subunit I of cytochrome c oxidase (nt 5904-7444). These mutations, in the following referred to as COX I mutations, are located at nt 6721 and nt 6742, affecting amino acids M273 and I280, respectively, of the human sequence.

Patient No. 1

A heteroplasmic mutation was detected by RFLP analysis of unfractionated bone marrow cells when Rsa I digestion of mtDNA segment no. 7 (nt 6504-7608) showed an aberrant pattern with two unexpected bands representing fragments of 281 and 216 bp length (Fig 2, lane 9). Their appearance implied the presence of a new Rsa I site, because the two regular sites in this segment (nt 6999 and 7013) only explained fragments of 594 and 497 bp and a very short fragment of 14 bp that was not visualized in the gel. The relative intensities of bands were estimated by gel photography with an electronic camera and data analysis with suitable software (Enhanced analysis system, EASY plus; Herolab GmbH, Wiesloch, Germany). The system sums up the light intensities of all pixels belonging to a specific band (with automatic background subtraction). The intensities were 182, 113, and 66, respectively, for the 497-bp band representing normal molecules and the 281-bp and 216-bp bands representing cleavage products of mutated mtDNA molecules. After correcting for molecular weight, this translated into 49% mutated mtDNA in the patient's bone marrow.

Fig. 2.

Detection of a heteroplasmic mtDNA mutation in a bone marrow aspirate from patient no. 1. RFLP analysis of mtDNA segment 7 (nt 6504-7608) with Cfo I in four patients (lanes 1 through 4) and with Rsa I in the same four patients (lanes 6 through 9) showed an abnormal restriction pattern in patient no. 1 (lane 9); for explanation, see text. Lane 5, DNA size marker (pGEM).

Fig. 2.

Detection of a heteroplasmic mtDNA mutation in a bone marrow aspirate from patient no. 1. RFLP analysis of mtDNA segment 7 (nt 6504-7608) with Cfo I in four patients (lanes 1 through 4) and with Rsa I in the same four patients (lanes 6 through 9) showed an abnormal restriction pattern in patient no. 1 (lane 9); for explanation, see text. Lane 5, DNA size marker (pGEM).

The same proportion (50% mutated mtDNA) appeared when the calculation was based on data of another experiment that was performed for analysis of different cell lineages (Fig 3). This experiment involved shortening of segment no. 7. A 420-bp PCR product, defined by primers A (nt 6504-6523) 5′-GTCCTAGCTGCTGGCATCAC-3′ and B* (nt 6923-6904) 5′-TCAGAGCACTGCAGCAGATC-3′, contained the mutation but no regular Rsa I site. It therefore remained undigested in controls (the patient's mother and two daughters) and in the patient's buccal mucosa cells and lymphocytes (the faint pathologic band in T lymphocytes was inconsistent and may have been due to contamination with phagocytes during immunomagnetic bead isolation of lymphocytes). In contrast, 50% of the PCR product was cut into two fragments of 216 and 204 bp when DNA from bone marrow, whole blood, or granulocytes was examined. For unknown reasons, platelets showed a lower percentage of mutated mtDNA (20%). Lymphocytes from another peripheral blood sample were also isolated with immunomagnetic beads and used for a repeat analysis (Fig 4). This time, the Rsa I restriction pattern of the full-length mtDNA segment no. 7 was clearly normal with T and B lymphocytes (no faint pathologic bands). This pattern of lineage involvement, and the absence of the mutation in the patient's mother and daughters, excluded an inherited mutation. We suggest that the mutation arose in a myeloid stem cell of the colony-forming unit granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM) type, although we cannot exclude with certainty the involvement of a pluripotent hematopoietic stem cell. The aberrant pattern was not detectable in 10 other patients with sideroblastic anemia, 8 patients with other types of MDS, and 50 hematologically normal controls (data not shown).

Fig. 3.

Cell lineage involvement of the COX I mutation in patient no. 1. Total DNA was extracted from different types of cells: Bm, bone marrow; Bl, peripheral blood; Plt, platelets; G, erythrocyte/granulocyte pellet; T, T lymphocytes; B, B lymphocytes; Mu, buccal mucosa cells; lane 8, DNA size marker; M, peripheral blood from the mother of patient no. 1; D1 and D2, peripheral blood from the first and second daughter of patient no. 1. See text for explanation of the restriction pattern.

Fig. 3.

Cell lineage involvement of the COX I mutation in patient no. 1. Total DNA was extracted from different types of cells: Bm, bone marrow; Bl, peripheral blood; Plt, platelets; G, erythrocyte/granulocyte pellet; T, T lymphocytes; B, B lymphocytes; Mu, buccal mucosa cells; lane 8, DNA size marker; M, peripheral blood from the mother of patient no. 1; D1 and D2, peripheral blood from the first and second daughter of patient no. 1. See text for explanation of the restriction pattern.

Fig. 4.

Cell lineage involvement of the COX I mutation in patient no. 1. Immunomagnetic bead isolation of T and B lymphocytes was repeated with another peripheral blood sample, and a normal Rsa I restriction pattern of mtDNA segment 7 (nt 6504-7608) was obtained for T and B lymphocytes. For abbreviations, see Fig 3.

Fig. 4.

Cell lineage involvement of the COX I mutation in patient no. 1. Immunomagnetic bead isolation of T and B lymphocytes was repeated with another peripheral blood sample, and a normal Rsa I restriction pattern of mtDNA segment 7 (nt 6504-7608) was obtained for T and B lymphocytes. For abbreviations, see Fig 3.

An mtDNA fragment containing the mutation was cloned in E coli. Five clones were sequenced; three yielded the wild-type sequence and two showed a point mutation characterized by a T → C transition at nt 6721 (Fig 5). The mutation changes an ATG codon to ACG, thus causing an amino acid change from methionine to threonine. Complementary strands of mtDNA were also sequenced and showed the expected A → G transition at nt 6721 (data not shown).

Fig. 5.

Sequencing of the COX I mutation in patient no. 1. mtDNA light strand; normal sequence on the left, mutated sequence on the right. The pathologic clone showed a T → C transition at nt 6721.

Fig. 5.

Sequencing of the COX I mutation in patient no. 1. mtDNA light strand; normal sequence on the left, mutated sequence on the right. The pathologic clone showed a T → C transition at nt 6721.

On RFLP analysis in patient no. 1, we also detected a hitherto unknown homoplasmic Taq I polymorphism at nucleotide position 8958 (Fig 6). Cloning and sequencing (data not shown) showed a C → T transition, changing the Taq I recognition sequence TCGA to TTGA. This polymorphism, located within the gene for ATPase subunit 6, is not associated with an amino acid change. As shown in Fig 6, the polymorphism was present in the blood cells of patient no. 1 and her two daughters. This inherited homoplasmic genetic marker stands in contrast to the acquired heteroplasmic mutation at nt 6721, which occurred in the patient's hematopoietic system and was detectable neither in cells of extramedullary origin nor in the patient's relatives.

Fig. 6.

Detection of a homoplasmic polymorphism in patient no. 1 and her two daughters. PCR-amplified mtDNA segment no. 9 (nt 8282-9262) was treated with Taq I. According to the Cambridge sequence, Taq I has a restriction site at nt 8957, which divides the segment of 981 bp into two fragments of 676 and 305 bp. In patient no. 1 (lane P1) and her two daughters (D1 and D2), complete (homoplasmic) loss of the restriction site left the PCR product intact after Taq I digestion, whereas the expected cleavage occurred in four other patients (C1 through 4). Lane 4, DNA size marker (pGEM).

Fig. 6.

Detection of a homoplasmic polymorphism in patient no. 1 and her two daughters. PCR-amplified mtDNA segment no. 9 (nt 8282-9262) was treated with Taq I. According to the Cambridge sequence, Taq I has a restriction site at nt 8957, which divides the segment of 981 bp into two fragments of 676 and 305 bp. In patient no. 1 (lane P1) and her two daughters (D1 and D2), complete (homoplasmic) loss of the restriction site left the PCR product intact after Taq I digestion, whereas the expected cleavage occurred in four other patients (C1 through 4). Lane 4, DNA size marker (pGEM).

Patient No. 2

When the mutation at nt 6721 had been detected in patient no. 1, the other patients in our series were screened for mutations in the COX I region by TGGE analysis. As a result, a further COX I mutation was found in patient no. 2 that had not been detected by RFLP analysis. Figure 7 shows a typical heteroduplex finding in perpendicular TGGE, and Fig 8 shows a parallel TGGE with heteroduplex bands of patients no. 1 and 2 in comparison with normal findings. DNA sequencing showed that the mutation in patient no. 2 was a T → C transition at nt 6742 (Fig 9). This mutation changes an amino acid from isoleucine (ATT) to threonine (ACT). It also creates a restriction site for Bsr I (ACTGGN ↓), which permitted screening of different cell lineages in this patient, too. Figure 10 clearly shows that skin fibroblasts and buccal mucosa cells were not affected by the mutation, whereas myeloid cells showed the abnormal restriction pattern. Analysis of band intensities showed a proportion of 52% mutated mtDNA in the bone marrow, 59% in a peripheral blood sample, and 71% in platelets. Faint pathologic bands in B and T lymphocytes could again be due to contamination with phagocytic cells during immunomagnetic bead isolation of lymphocytes or represent a low percentage of mutated mtDNA in lymphocytes. As in patient no. 1, the data suggest that the mutation was restricted to the hematopoietic system.

Fig. 7.

Perpendicular TGGE in patient no. 2. MtDNA fragment, nt 6504-6923. 5% polyacrylamide gel, silver staining. The typical heteroduplex pattern (two clearly separated heteroduplex bands on the left, two homoduplex bands not clearly separated on the right) indicates the presence of two homologous mtDNA species (wild-type and mutated), which after a cycle of denaturation and renaturation produce hybrids differing in their melting behavior.

Fig. 7.

Perpendicular TGGE in patient no. 2. MtDNA fragment, nt 6504-6923. 5% polyacrylamide gel, silver staining. The typical heteroduplex pattern (two clearly separated heteroduplex bands on the left, two homoduplex bands not clearly separated on the right) indicates the presence of two homologous mtDNA species (wild-type and mutated), which after a cycle of denaturation and renaturation produce hybrids differing in their melting behavior.

Fig. 8.

Parallel TGGE. Same mtDNA fragment as in Fig 7. After denaturation and renaturation, each PCR product was brought onto the gel in triplicate at time intervals of 15 minutes (lanes a, b, and c, respectively). The running time was too long for the samples designated a and b, so that bands became diffuse. Clear bands can be seen in lanes c. M, D1, and D2, normal bands in the mother and two daughters of patient no. 1, respectively; T and Mu, normal bands in T lymphocytes and buccal mucosa cells of patient no. 1, respectively; P1 and P2, heteroduplex bands in patients no. 1 and 2, respectively; Co, normal bands in an additional control person.

Fig. 8.

Parallel TGGE. Same mtDNA fragment as in Fig 7. After denaturation and renaturation, each PCR product was brought onto the gel in triplicate at time intervals of 15 minutes (lanes a, b, and c, respectively). The running time was too long for the samples designated a and b, so that bands became diffuse. Clear bands can be seen in lanes c. M, D1, and D2, normal bands in the mother and two daughters of patient no. 1, respectively; T and Mu, normal bands in T lymphocytes and buccal mucosa cells of patient no. 1, respectively; P1 and P2, heteroduplex bands in patients no. 1 and 2, respectively; Co, normal bands in an additional control person.

Fig. 9.

Sequencing of the COX I mutation in patient no. 2. mtDNA heavy strand; normal sequence on the right, mutated sequence on the left. The pathologic clone showed an A → G transition at nt 6742. The complementary light strand was also sequenced and showed the expected T → C transition (data not shown).

Fig. 9.

Sequencing of the COX I mutation in patient no. 2. mtDNA heavy strand; normal sequence on the right, mutated sequence on the left. The pathologic clone showed an A → G transition at nt 6742. The complementary light strand was also sequenced and showed the expected T → C transition (data not shown).

Fig. 10.

Cell lineage involvement of the COX I mutation in patient no. 2. Total DNA was extracted from different types of cells: Bm, bone marrow; Bl, peripheral blood; Plt, platelets; B, B lymphocytes; T, T lymphocytes; Mu, buccal mucosa cells; SF, skin fibroblasts; Co, control bone marrow samples; lane 8, DNA size marker. In affected cell lineages, the COX I mutation creates a restriction site for Bsr I in the mtDNA segment nt 6504-6923, so that a considerable proportion of the 420-bp PCR product is cleaved into fragments of 243 and 177 bp.

Fig. 10.

Cell lineage involvement of the COX I mutation in patient no. 2. Total DNA was extracted from different types of cells: Bm, bone marrow; Bl, peripheral blood; Plt, platelets; B, B lymphocytes; T, T lymphocytes; Mu, buccal mucosa cells; SF, skin fibroblasts; Co, control bone marrow samples; lane 8, DNA size marker. In affected cell lineages, the COX I mutation creates a restriction site for Bsr I in the mtDNA segment nt 6504-6923, so that a considerable proportion of the 420-bp PCR product is cleaved into fragments of 243 and 177 bp.

Interspecies Comparison

The positions of both mutations are in close proximity to each other within subunit I of cytochrome oxidase and affect amino acids M273 and I280 of the human sequence. During evolution, methionine and isoleucine in these positions have been strongly conserved, as shown by interspecies comparison (Table 1). Furthermore, high resolution screening of human populations involving hundreds of individuals has never shown restriction site polymorphisms at nt 6721 or 6742.36

Table 1.

Interspecies Comparison of Amino Acid Sequences in the COX I Region

          
Bacillus subtilis 
Escherichia coli 
Paracoccus denitrificans 
Thermus thermophilus 
Chlamydomonas reinhardtii 
Yeast (Saccharomyces cerevisiae
Wheat (Triticum aestivum
Drosophila melanogaster 
Honey bee (Apis mellifera
Worm (Strongyloides purpuratus
Worm (Lumbricus terrestris
Sea urchin (Paracentrotus lividus
Cod (Gadus morhua
Carp (Cyprinus carpio
Trout (Oncorhynchus mykiss
Frog (Xenopus laevis
Seal (Phoca vitulina
Whale (Balaenoptera musculus
Chicken (Gallus gallus
Mouse (Mus musculus
Opossum (Didelphis virginiana
Rhinoceros unicornis 
Cattle (Bos taurus
Gorilla (G gorilla
Chimpanzee (Pan troglodytes
Man (Homo sapiens
Patient no. 1 
                     
Patient no. 2 
                     
 
          
          
Bacillus subtilis 
Escherichia coli 
Paracoccus denitrificans 
Thermus thermophilus 
Chlamydomonas reinhardtii 
Yeast (Saccharomyces cerevisiae
Wheat (Triticum aestivum
Drosophila melanogaster 
Honey bee (Apis mellifera
Worm (Strongyloides purpuratus
Worm (Lumbricus terrestris
Sea urchin (Paracentrotus lividus
Cod (Gadus morhua
Carp (Cyprinus carpio
Trout (Oncorhynchus mykiss
Frog (Xenopus laevis
Seal (Phoca vitulina
Whale (Balaenoptera musculus
Chicken (Gallus gallus
Mouse (Mus musculus
Opossum (Didelphis virginiana
Rhinoceros unicornis 
Cattle (Bos taurus
Gorilla (G gorilla
Chimpanzee (Pan troglodytes
Man (Homo sapiens
Patient no. 1 
                     
Patient no. 2 
                     
 
          

The amino acids mutated in patients no. 1 and 2, Met273 and Ile280 according to the human sequence, have been strongly conserved during evolution. Sequence data are from earlier studies.29,72-93 

mtDNA From Clonal Cultures

Whereas erythropoietic cell growth in culture was completely lacking in patient no. 1, erythropoietic clusters and some smaller colonies were observed in patient no. 2. Growth of colony-forming units-granulocyte (CFU-G) and colony-forming units-monocyte (CFU-M) appeared unimpaired in both patients. PCR amplification and RFLP analysis of the mtDNA segment containing the COX I mutation showed that all clusters and colonies that we picked (erythropoietic, granulocytic, and monocytic) showed the same pathologic restriction pattern as the mtDNA derived from uncultured blood or bone marrow cells of the respective patient (data not shown). The percentage of mutated mtDNA varied between different colonies, but the average percentage was similar to that observed in whole blood or bone marrow samples. In patient no. 2, there was no significant difference in the percentage of mutated mtDNA between erythropoietic clusters and granulocytic colonies.

DISCUSSION

The finding of mtDNA mutations affecting cytochrome c oxidase supports our hypothesis that AISA is a disorder involving mitochondrial respiratory chain dysfunction.14 Cytochrome c oxidase (COX) is a good candidate for playing a major role in mitochondrial iron metabolism. A strong hint in this direction comes from the copper connection,37 which refers to the close relation between copper and iron in hematopoiesis, including the role of copper in mitochondrial iron metabolism. COX is the only respiratory chain complex that contains copper, namely CuA1 and CuA2 in subunit II and CuB in subunit I.38,39 Copper is an essential part of the metal redox centers of this enzyme complex. Intriguingly, copper deficiency can cause sideroblastic anemia, with usually moderate numbers of ring sideroblasts.40-47 Williams et al48 found that mitochondria isolated from copper-deficient animals were deficient in COX activity and failed to synthesize heme from Fe3+ and protoporphyrin at the normal rate. The rate of heme synthesis correlated with the COX activity. Through experiments with respiratory chain inhibitors, these investigators confirmed that an active and intact electron transport chain is required for the reduction of Fe3+ on the inner mitochondrial membrane and for a supply of Fe2+ as substrate for ferrochelatase. Williams et al48 suggested that electrons may be donated to Fe3+ from cytochrome c oxidase. Because both COX I mutations that we identified are located in transmembrane helix no. VII in the immediate vicinity of the heme a3 -CuB center,38 it is tempting to speculate that this metal redox center is involved in supplying electrons to Fe3+.

The copper connection has recently been strengthened by the finding that high-affinity transmembrane uptake of iron in Saccharomyces cerevisiae requires copper. This is explained by the involvement of a copper-containing oxidoreductase, FET3, in iron uptake.49,50 Yeast mutants defective in the fet3 gene are deficient in high-affinity Fe2+ transport, and copper depletion of wild-type S cerevisiae also results in a selective reversible decrease in Fe2+ transporter activity. The FET3 protein exhibits extensive similarity to the familiy of blue multicopper oxidoreductases, an enzyme superfamily that also includes mitochondrial cytochrome c oxidase.

Both COX I mutations fulfill the criteria that are generally applied to exclude nonpathogenic polymorphisms of mtDNA, namely (1) the observed nucleotide change is absent in unaffected individuals; (2) it occurs in an evolutionary conserved region; and (3) the mutation displays heteroplasmy. As far as the first criterion is concerned, data are available from extensive population genetic studies involving more than 1,800 individuals from various ethnic backgrounds.36,51-61 To our knowledge, these studies never identified nucleotide changes in positions 6721 or 6742 of the mitochondrial genome. The second criterion is not reliable, because mutations of conserved nucleotides can occur without having a direct effect on the clinical phenotype.62 The third criterion, heteroplasmy, requires special consideration. When an mtDNA mutation arises, it creates an intracellular mixture of mutant and normal mtDNA molecules called heteroplasmy. Heteroplasmy is considered an indicator for pathogenic mutations because it is typical of diseases associated with defects of mtDNA, but generally absent in normal individuals.63,64 Accordingly, the COX I mutations in patients no. 1 and 2 are heteroplasmic, whereas the inherited nonpathogenic polymorphism at nt 8958 in patient no. 1, her mother, and her two daughters is homoplasmic. However, it must be realized that heteroplasmy of an acquired mtDNA mutation in the hematopoietic system is not quite the same as heteroplasmy in postmitotic tissues such as muscle or nerve. The matter is more complicated in the bone marrow because the dynamics of hematopoietic cell proliferation must be taken into account. Thus, the degree of heteroplasmy that we observed with the two COX mutations may reflect a balance between (1) a putative replicative advantage of mutated mtDNA over wild-type mtDNA, (2) the proliferative advantage of the cells belonging to the pathologic clone of sideroblastic anemia, and (3) a proliferative disadvantage of cells containing a particularly high proportion of mutated mtDNA.

A very interesting aspect of heteroplasmy is its potential to explain a peculiar feature of AISA, namely the heterogeneity in the degree of mitochondrial iron accumulation. Not all erythroblasts in AISA are ring sideroblasts, and not all ring sideroblasts show the same degree of mitochondrial iron overload. This heterogeneity has also been demonstrated within single erythroid colonies cultured in vitro.65-67 Whereas such intraclonal heterogeneity is hard to explain in terms of mutations involving nuclear genes, mtDNA mutations could easily account for the phenomenon. Each cell contains hundreds of mitochondria and thousands of copies of the mitochondrial genome. Therefore, cells can harbor mixtures of mutant and normal mtDNAs (heteroplasmy), and each time a heteroplasmic cell divides, the mutant and normal mtDNAs are randomly segregated into the daughter cells.15 In each cell, the severity of the resulting respiratory chain defect depends on the proportion of mutated mtDNA. A heterogeneous population consisting of normal and grossly abnormal as well as intermediate cells can thus be the consequence of an mtDNA mutation.

It is conceivable that the COX mutations that we identified mainly disturb the process of mitochondrial iron reduction, without producing significant impairment of other respiratory chain functions. Although such a defect would interfere with the major metabolic activity of erythroblasts (ie, heme synthesis), causing considerable damage through secondary effects of iron loading, its consequences may be minimal for other cell lineages. In accordance with a defect primarily disturbing erythropoiesis, we found that erythropoietic colony growth (burst-forming unit-erythroid [BFU-E] and colony-forming unit-erythroid [CFU-E]) was virtually absent or severely impaired, whereas growth of CFU-GM was not significantly reduced, despite the fact that cells in granulocyte and macrophage colonies carried the same mtDNA mutation.

In general, mtDNA mutations associated with mitochondrial diseases arise in the female germline and are present in various tissues, albeit at widely differing percentages. To our knowledge, the two COX mutations described (and a mitochondrial tRNA mutation that we recently reported23 ) are the first examples of disease-associated mtDNA mutations that are specifically related to a particular organ, ie, the hematopoietic system. As a prerequisite for this unusual constellation, a mtDNA mutation must arise in a hematopoietic stem cell, which in turn must populate the bone marrow in a dominant fashion. The clonal expansion that is necessary to spread the mtDNA mutation in the bone marrow cannot be effectuated by the mtDNA mutation per se, because severe mutations of mtDNA are known to produce a growth handicap rather than a growth advantage for proliferating cells.25,68,69 A hematopoietic stem cell affected with a pathogenic mtDNA mutation must therefore acquire an additional nuclear mutation conferring growth advantage to become capable of establishing a clonal bone marrow disease such as sideroblastic anemia. In patient no. 2, the 5q− anomaly may have been the transforming event.

The mtDNA mutations reported here fit into the mitochondrial-DNA mutation hypothesis of cell ageing,70,71 which is based on (1) an approximately 10 to 20 times higher frequency of mutations in mitochondrial as compared with nuclear DNA; (2) the compactness of the mitochondrial genome (no introns), increasing the probability that mutations will affect functionally important regions; (3) the lack of sufficient repair mechanisms; and (4) the increased production of oxygen radicals in mitochondria with increasing age, promoting chemical modification of mitochondrial proteins and mtDNA. Apparently, hematopoietic stem cells must be included among cells suffering age-related changes to their mitochondrial genome.25 

Supported by Deutsche Forschungsgemeinschaft (Grant No. Ga 527/1-1), Leukämie-Liga e.V., and Ministerium für Wissenschaft und Forschung des Landes Nordrhein-Westfalen.

Presented in part at the Joint Annual Meeting of the German and Austrian Societies for Hematology and Oncology, October 4-7, 1996, Düsseldorf, Germany.

Address reprint requests to Norbert Gattermann, MD, PhD, Klinik für Hämatologie, Onkologie und Klinische Immunologie, Heinrich-Heine-Universität, Moorenstraβe 5, D-40225 Düsseldorf, Germany.

REFERENCES

REFERENCES
1
Cotter
PD
Rucknagel
DL
Bishop
DF
X-linked sideroblastic anemia: Identification of the mutation in the erythroid-specific δ-aminolevulinate synthase (ALAS2) gene in the original family described by Cooley.
Blood
84
1994
3915
2
Cox
TC
Bottomley
SS
Wiley
JS
Bawden
MJ
Matthews
CS
May
BK
X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase.
N Engl J Med
330
1994
675
3
Cotter
PD
May
A
Fitzsimons
EJ
Houston
T
Woodcock
BE
Al-Sabah
AI
Wong
L
Bishop
DF
Late-onset X-linked sideroblastic anemia.
J Clin Invest
96
1995
2090
4
May
A
Fitzsimons
EJ
Sideroblastic anaemia.
Clin Haematol
7
1994
851
5
Prades
E
Chambon
C
Dailey
TA
Dailey
HA
Briere
J
Grandchamp
B
A new mutation of the ALAS2 gene in a large familiy with X-linked sideroblastic anemia.
Hum Genet
95
1995
424
6
Bottomley
SS
May
BK
Cox
TC
Cotter
PD
Bishop
DF
Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia.
J Bioenergetics Biomembranes
27
1995
161
7
Edgar
AJ
Losowsky
MS
Noble
JS
Wickramasinghe
SN
Identification of an arginine452 to histidine substitution in the erythroid 5-aminolaevulinate synthetase gene in a large pedigree with X-linked hereditary sideroblastic anaemia.
Eur J Haematol
58
1997
1
8
Kushner
JP
Lee
GR
Wintrobe
MM
Cartwright
GE
Idiopathic refractory sideroblastic anemia. Clinical and laboratory investigation of 17 patients and review of the literature.
Medicine
50
1971
139
9
Pasanen
AVO
Vuopio
P
Borgström
GH
Tenhunen
R
Haem biosynthesis in refractory sideroblastic anaemia associated with the preleukaemic syndrome.
Scand J Haematol
27
1981
35
10
Grasso
JA
Myers
TJ
Hines
JD
Sullivan
AL
Energy-dispersive X-ray analysis of the mitochondria of sideroblastic anaemia.
Br J Haematol
46
1980
57
11
Porra
RJ
Jones
OTG
Studies on ferrochelatase.
Biochem J
87
1963
181
12
Romslo
I
Energy-dependent accumulation of iron by isolated rabbit reticulocyte mitochondria.
Biochim Biophys Acta
357
1974
34
13
Flatmark
T
Romslo
I
Energy-dependent accumulation of iron by isolated rat liver mitochondria. Requirement for reducing equivalents and evidence for a unidirectional flux of Fe(II) across the inner membrane.
J Biol Chem
250
1975
6433
14
Gattermann
N
Aul
C
Schneider
W
Is acquired idiopathic sideroblastic anemia (AISA) a disorder of mitochondrial DNA?
Leukemia
7
1993
2069
15
Wallace
DC
Diseases of the mitochondrial DNA.
Annu Rev Biochem
61
1992
1175
16
Johns
DR
The other human genome: Mitochondrial DNA and disease.
Nat Med
2
1996
1065
17
Pearson
HA
Lobel
JS
Kocoshis
SA
Naiman
JL
Windmiller
J
Lammi
AT
Hoffman
R
Marsh
JC
A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction.
J Pediatr
95
1979
976
18
Bader-Meunier
B
Rötig
A
Mielot
F
Lavergne
JM
Croisille
L
Rustin
P
Landrieu
P
Dommergues
JP
Munnich
A
Tchernia
G
Refractory anaemia and mitochondrial cytopathy in childhood.
Br J Haematol
87
1994
381
19
Smith
OP
Hann
IM
Woodward
CE
Brockington
M
Pearson's marrow/pancreas syndrome: Haematological features associated with deletion and duplication of mitochondrial DNA.
Br J Haematol
90
1995
469
20
Rötig
A
Colonna
M
Bonnefont
JP
Blanche
S
Fischer
A
Saudubray
JM
Munnich
A
Mitochondrial DNA deletion in Pearson's marrow/pancreas syndrome.
Lancet
1
1989
902
21
Rötig
A
Cormier
V
Koll
F
Mize
CE
Saudubray
J-M
Veerman
A
Pearson
HA
Munnich
A
Site-specific deletions of the mitochondrial genome in the Pearson marrow-pancreas syndrome.
Genomics
10
1991
502
22
Gattermann
N
Lotz
H
Aul
C
Schneider
W
No large deletions of mitochondrial DNA in acquired idiopathic sideroblastic anemia (AISA).
Am J Hematol
41
1992
297
23
Gattermann
N
Retzlaff
S
Wang
Y-L
Berneburg
M
Heinisch
J
Wlaschek
M
Aul
C
Schneider
W
A heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in non-lymphoid cell lineages from a patient with acquired idiopathic sideroblastic anaemia.
Br J Haematol
93
1996
845
24
Aul
C
Runde
V
Gattermann
N
All-trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study.
Blood
82
1993
2967
25
Gattermann
N
Berneburg
M
Heinisch
J
Aul
C
Schneider
W
Detection of the ageing-associated 5-Kb deletion of mitochondrial DNA in blood and bone marrow of hematologically normal adults. Absence of the deletion in clonal bone marrow disorders.
Leukemia
9
1995
1704
26
Shuster
RC
Rubenstein
AJ
Wallace
DC
Mitochondrial DNA in anucleate human blood cells.
Biochem Biophys Res Commun
155
1988
1360
27
Rapaport
SM
Schewe
T
The maturational breakdown of mitochondria in reticulocytes.
Biochim Biophys Acta
864
1986
471
28
Fleischmajer
R
Perlish
JS
Krieg
T
Timpl
R
Variability in collagen and fibronectin synthesis by skleroderma fibroblasts in primary culture.
J Invest Dermatol
76
1981
400
29
Anderson
S
Banitier
AT
Barren
BG
De Bruijn
MHL
Coulson
AR
Droui
J
Eperon
IC
Nierlich
DP
Roe
BA
Sanger
F
Schreier
PH
Smith
AJH
Staden
R
Young
IG
Sequence and organization of the human mitochondrial genome.
Nature
290
1981
457
30
Myers
RM
Maniatis
T
Lerman
LS
Detection and localization of single base changes by denaturing gradient gel electrophoresis.
Methods Enzymol
155
1987
501
31
Riesner
D
Steger
G
Zimmat
R
Owens
RA
Wagenhöfer
M
Hillen
W
Vollbach
S
Henco
K
Temperature-gradient gel electrophoresis of nucleic acids: Analysis of conformational transitions, sequence variations, and protein-nucleic acid interactions.
Electrophoresis
10
1989
377
32
Riesner D, Henco K, Steger G: Temperature-gradient gel electrophoresis: A method for the analysis of conformational transitions and mutations in nucleic acids and proteins., in Chrambach A, Dunn MJ, Radola BJ (eds): Advances in Electrophoresis. Weinheim, Germany, VCH Verlagsgesellschaft, 1990, p
33
Yanisch-Perron
C
Vieira
J
Messing
J
Improved M13 phage cloning vectors and host strains: Nucleotitde sequences of the M13mp18 and pUC19 vectors.
Gene
33
1985
103
34
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
35
Sanger
F
Nicklen
S
Coulson
AR
DNA sequencing with chain-terminating inhibitors.
Proc Natl Acad Sci USA
74
1977
5463
36
Wallace DC, Lott MT, Torroni A, Brown MD, Shoffner JM: Report of the committee on human mitochondrial DNA, in Cutichia AJ, Pearson PL (eds): Human Gene Mapping 1993. Baltimore, MD, Johns Hopkins, 1994, p 813
37
Frieden
E
The copper connection.
Semin Hematol
20
1983
114
38
Iwata
S
Ostermeier
C
Ludwig
B
Michel
H
Structure at 2.8 A resolution of cytochrome c oxidase from Paracoccus denitrificans.
Nature
376
1995
660
39
Tsukihara
T
Aoyama
H
Yamashita
E
Tomizaki
T
Yamaguchi
H
Shinzawa-Itoh
K
Nakashima
R
Yaono
R
Yoshikawa
S
Structures of metal sites of oxidized bovine heart cytochrome c oxidase at 2.8 A.
Science
269
1995
1069
40
Ashkenazi
A
Levin
S
Djaldetti
M
Fishel
E
Benvenisti
D
The syndrome of neonatal copper deficiency.
Pediatrics
52
1973
525
41
Dunlap
WM
Watson
JG
Hume
DM
Anemia and neutropenia caused by copper deficiency.
Ann Intern Med
80
1974
470
42
Vilter
RW
Bozian
RC
Hess
EV
Manifestations of coppper deficiency in a patient with systemic sclerosis on intravenous hyperalimentation.
N Engl J Med
291
1974
188
43
Zidar
BL
Shadduck
RK
Zeigler
Z
Winkelstein
A
Observations on the anemia and neutropenia of human copper deficiency.
Am J Hematol
3
1977
177
44
Williams
DM
Copper deficiency in humans.
Semin Hematol
20
1983
118
45
Hirase
X
Abe
Y
Sadamura
S
et al
Anemia and neutropenia in a case of copper deficiency: Role of copper in normal hematopoiesis.
Acta Haematol
87
1992
195
46
Bottomley SS: Sideroblastic anemias, in Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN (eds): Wintrobe's Clinical Hematology. Philadelphia, PA, Lea & Febiger, 1993, p 852
47
Fiske
DN
McCoy
HE
Kitchens
CS
Zinc-induced sideroblastic anemia: Report of a case, review of the literature, and desription of the hematologic syndrome.
Am J Hematol
46
1994
147
48
Williams
DM
Loukopoulos
D
Lee
GR
Cartwright
GE
Role of copper in mitochondrial iron metabolism.
Blood
48
1976
77
49
Dancis
A
Yuan
DS
Haile
D
Askwith
C
Eide
D
Moehle
C
Kaplan
J
Klausner
RD
Molecular characterization of a copper transport protein in S. cerevisiae: An unexpected role for copper in iron transport.
Cell
76
1994
393
50
Askwith
C
Eide
D
Van Ho
A
Bernard
PS
Li
L
Davis-Kaplan
S
Sipe
DM
Kaplan
J
The FET3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake.
Cell
76
1994
403
51
Ballinger
SW
Schurr
TG
Torroni
A
Gan
YY
Hodge
JA
Hassan
K
Chen
K-H
Wallace
DC
Southeast asian mitochondrial DNA analysis reveals genetic continuity of ancient mongoloid migrations.
Genetics
130
1992
139
52
Cann
RL
Brown
WM
Wilson
AC
Polymorphic sites and the mechanism of evolution in human mitochondrial DNA.
Genetics
106
1984
479
53
Cann
RL
Stoneking
M
Wilson
AC
Mitochondrial DNA and human evolution.
Nature
325
1987
31
54
Stoneking
M
Jorde
LB
Bhatia
K
Wilson
AC
Geographic variation in human mitochondrial DNA from Papua New Guinea.
Genetics
124
1990
717
55
Passarino
G
Semino
O
Modiano
G
Santachiara-Benerecetti
AS
COII/tRNA(Lys) intergenic 9-bp deletion and other mtDNA markers clearly reveal that the Tharus (Southern Nepal) have oriental affinities.
Am J Hum Genet
53
1993
609
56
Torroni
A
Schurr
TG
Yang
C-C
Szathmary
EJE
Williams
RC
Schanfield
MS
Troup
GA
Knowler
WC
Lawrence
DN
Weiss
KM
Wallace
DC
Native american mitochondrial DNA analysis indicates that the Amerind and Nadene populations were founded by two independent migrations.
Genetics
130
1992
152
57
Torroni
A
Schurr
TG
Cabell
MF
Brown
MD
Neel
JF
Larsen
M
Smith
DG
Vullo
CM
Wallace
DC
Asian affinities and continental radiation of the four founding Native American mtDNAs.
Am J Hum Genet
53
1993
563
58
Torroni
A
Sukernik
RI
Schurr
TG
Starikovskaya
YB
Cabell
MF
Crawford
MH
Comuzzie
AG
Wallace
DC
MtDNA variation of aboriginal Siberians reveals distinct genetic affinities with Native Americans.
Am J Hum Genet
53
1993
591
59
Torroni
A
Neel
JV
Barrantes
R
Schurr
TG
Wallace
DC
A mitochondrial DNA “clock” for the Amerinds and its implication for timing their entry into North America.
Proc Natl Acad Sci USA
91
1994
1158
60
Torroni
A
Chen
Y
Semino
O
Santachiara-Beneceretti
AS
Scott
CR
Lott
MT
Winter
M
Wallace
DC
Mitochondrial DNA and Y-chromosome polymorphisms in four native american populations from southern Mexico.
Am J Hum Genet
54
1994
303
61
Torroni
A
Lott
MT
Cabell
MF
Chen
Y
Laverge
L
Wallace
DC
Mitochondrial DNA and the origin of Caucasians. Identification of ancient Caucasian-specific haplogroups, one of which is prone to a recurrent somatic duplication in the D-loop region.
Am J Hum Genet
55
1994
760
62
van den Ouweland
JMW
Bruining
GJ
Lindhout
D
Wit
J-M
Veldhuyzen
BFE
Maassen
JA
Mutations in mitochondrial tRNA genes: non-linkage with syndromes of Wolfram and chronic progressive external ophthalmoplegia.
Nucleic Acids Res
20
1992
679
63
Zeviani
M
Gellera
C
Antozzi
C
Rimoldi
M
Morandi
L
Villani
F
Tiranti
V
DiDonato
S
Maternally inherited myopathy and cardiomyopathy: Association with mutation in mitochondrial DNA tRNALeu(UUR).
Lancet
338
1991
143
64
Wallace
DC
Mitochondrial DNA sequence variation in human evolution and disease.
Proc Natl Acad Sci USA
91
1994
8739
65
Hutcheson
JR
Ogawa
M
Eguchi
M
Spicer
SS
Idiopathic sideroblastic anemia: Presence of sideroblastic changes in the erythropoietic precursors cultured from peripheral blood.
Exp Hematol
7
1979
328
66
Mizoguchi
H
Kubota
K
Suda
T
Takaku
F
Miura
Y
Erythroid and granulocyte/macrophage progenitor cells in primary acquired sideroblastic anemia.
Int J Cell Cloning
1
1983
15
67
Amenomori
T
Tomonaga
M
Jinnai
I
Soda
H
Nonaka
H
Matsuo
T
Yoshida
Y
Kuriyama
K
Ichimaru
M
Suematsu
T
Cytogenetic and cytochemical studies on progenitor cells of primary acquired sideroblastic anemia (PASA): Involvement of multipotent myeloid stem cells in PASA clone and mosaicism with normal clone.
Blood
70
1987
1367
68
Moraes
CT
Schon
EA
DiMauro
S
Miranda
AF
Heteroplasmy of mitochondrial genomes in clonal cultures from patients with Kearns-Sayre syndrome.
Biochem Biophys Res Commun
160
1989
765
69
Bourgeron
T
Chretien
D
Rötig
A
Munnich
A
Rustin
P
Fate and expression of the deleted mitochondrial DNA differ between human heteroplasmic skin fibroblast and Epstein-Barr virus-transformed lymphocyte cultures.
J Biol Chem
268
1993
19369
70
Joenje H: Molecular Basis of Aging: Mitochondrial Degeneration and Oxidative Damage. Special Issue of Mutation Research. Vol 275, Nos. 3-6, 1992
71
Shigenaga
MK
Hagen
TM
Ames
BN
Oxidative damage and mitochondrial decay in aging.
Proc Natl Acad Sci USA
91
1994
10771
72
Saraste
M
Structural features of cytochrome oxidase.
Q Rev Biophys
23
1990
331
73
Thomas
JW
Pustinen
A
Alben
JO
Gennis
RB
Wikström
M
Substitution of asparagine for aspartate-135 in subunit I of the cytochrome bo ubiquinol oxidase of Escherichia coli eliminates proton-pumping activity.
Biochemistry
32
1993
10923
74
Raitio
M
Jalli
T
Saraste
M
Isolation and analysis of the genes for cytochrome c oxidase in Paracoccus denitrificans.
EMBO J
6
1987
2825
75
Mather
MW
Springer
P
Hensel
S
Buse
G
Fee
JA
Cytochrome oxidase genes from Thermus thermophilus.
J Biol Chem
268
1993
5395
76
Vahrenholz
C
Pratje
E
Michaelis
G
Dujon
B
Mitochondrial DNA of Chlamydomonas rheinhardtii: Sequence and arrangement of URF5 and the gene for cytochrome oxidase subunit I.
Mol Gen Genet
201
1985
213
77
Bonitz
SG
Coruzzi
G
Thalenfeld
BE
Tzagoloff
A
Macino
G
Assembly of the mitochondrial membrane system. Structure and nucleotide sequence of the gene coding for subunit I of yeast cytochrome oxidase.
J Biol Chem
255
1980
11927
78
de Bruijn
MH
Drosophila melanogaster mitochondrial DNA, a novel organization and genetic code.
Nature
304
1983
234
79
Crozier
RH
Crozier
YC
The mitochondrial genome of the honeybee Apis mellifera: Complete sequence and genome organization.
Genetics
133
1993
97
80
Boore
JL
Brown
WM
Complete sequence of the mitochondrial DNA of the annelid worm Lumbricus terrestris.
Genetics
141
1995
305
81
Cantatore
P
Roberti
M
Rainaldi
G
Gadaleta
MN
Saccone
C
The complete nucleotide sequence, gene organization, and genetic code of the mitochondrial genome of Paracentrotus lividus.
J Biol Chem
264
1989
10965
82
Johansen
S
Johansen
T
Sequence analysis of 12 structural genes and a novel non-coding region from mitochondrial DNA of Atlantic cod, Gadus morhua.
Biochim Biophys Acta
1218
1994
213
83
Huang FL: Cyprinus carpio (carp) cytochrome c oxidase subunit I. EMBL data library accession no. X61010, 1992
84
Zardoya
R
Garrido-Pertierra
A
Bautista
JM
The complete nucleotide sequence of the mitochondrial DNA genome of the rainbow trout, Oncorhynchus mykiss.
J Mol Evol
41
1995
942
85
Roe
Ba
Ma
DP
Wilson
RK
Wong
FJ
The complete nucleotide sequence of the Xenopus laevis mitochondrial genome.
J Biol Chem
260
1985
9759
86
Arnason
U
Johnsson
E
The complete mitochondrial DNA sequence of the harbor seal, Phoca vitulina.
J Mol Evol
34
1992
493
87
Arnason
U
Gullberg
A
Comparison between the complete mtDNA sequences of the blue and the fin whale, two species that can hybridize in nature.
J Mol Evol
37
1993
312
88
Desjardins
P
Morais
R
Sequence and gene organization of the chicken mitochondrial genome. A novel gene order in higher vertebrates.
J Mol Biol
212
1990
599
89
Bibb
MJ
Van Etten
RA
Wright
CT
Walberg
MW
Clayton
DA
Sequence and gene organization of mouse mitochondrial DNA.
Cell
26
1981
167
90
Anderson
S
de Bruijn
MH
Coulson
AR
Eperon
IC
Sanger
F
Young
IG
Complete sequence of bovine mitochondrial DNA. Conserved features of the mammalian mitochondrial genome.
J Mol Biol
156
1982
683
91
Xu
X
Janke
A
Arnason
U
The complete mitochondrial DNA sequence of the greater indian rhinocerus, Rhinocerus unicornis, and the phylogenetic relationshipamong Carnivora, Perissodactylata, and Artiodactyla (+Cetacea).
Mol Biol Evol
13
1996
1167
92
Xu
X
Arnason
U
A complete sequence of the mitochondrial genome of the Western lowland gorilla.
J Mol Evol
3
1996
691
93
Arnason
U
Xu
X
Gullberg
A
Comparison between the complete mitochondrial DNA sequences of Homo sapiens and common chimpanzee based on non-chimaeric sequences.
J Mol Evol
42
1996
145